Prevalence of peripheral artery disease (PAD) and factors associated: An epidemiological analysis from the population-based Screening PRE-diabetes and type 2 DIAbetes (SPREDIA-2) study

V. Cornejo del Río¹,², J. Mostaza¹, C. Lahoz¹, V. Sánchez-Arroyo¹, C. Sabin¹, S. López¹, P. Patrón¹, P. Fernández-Garcia¹, B. Fernández-Puntero¹, D. Vicent¹,³, L. Montesano-Sánchez², F. García-Iglesias¹, T. González-Alegría¹, E. Estirado¹, E. Laguna¹, C. de Burgos-Lunar²,⁶, P. Gómez-Campeo³,⁷, J. C. Abanades-Herranz⁸, J. M. de Miguel-Yanes⁹, M. A. Salinero-Fort⁶,¹⁰*, on behalf SPREDIA-2 Group

¹Hospital Carlos III, Madrid, Spain, ²Grupo de Investigación en cuidados IdiPAZ, Hospital La Paz, Madrid, Spain, ³Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ), Madrid, Spain, ⁴Hospital de Fuenlabrada, Madrid, Spain, ⁵Dirección General de Salud Pública, Subdirección de Promoción, Prevención y Educación de la Salud, Consejería de Sanidad, Madrid, Spain, ⁶Red de Investigación en servicios de salud en enfermedades crónicas (REDISSEC), Madrid, Spain, ⁷Plataforma de Apoyo al Investigador Novel, IdiPAZ, Madrid, Spain, ⁸Centro de Salud Monóvar, Madrid, Spain, ⁹Hospital Gregorio Marañón, Madrid, Spain, ¹⁰Subdirección General de Investigación Sanitaria, Consejería de Sanidad, Madrid, Spain

¶The complete membership of the SPREDIA-2 Group can be found in the Acknowledgments.

* Miguel.Salinero@salud.madrid.org

Abstract

Aim
To describe the prevalence of Peripheral Artery Disease (PAD) in a random population sample and to evaluate its relationship with Mediterranean diet and with other potential cardiovascular risk factors such as serum uric acid and pulse pressure in individuals ranged 45 to 74 years.

Methods
Cross-sectional analysis of 1568 subjects (mean age 6.5 years, 43% males), randomly selected from the population. A fasting blood sample was obtained to determine glucose, lipids, and Hba1C levels. An oral glucose tolerance test was performed in non-diabetic subjects. PAD was evaluated by ankle–brachial index and/or having a prior diagnosis.

Results
PAD prevalence was 3.81% (95% CI, 2.97–4.87) for all participants. In men, PAD prevalence was significantly higher than in women [5.17% (95% CI, 3.74–7.11) vs. 2.78% (95% CI, 1.89–4.07); p = 0.014].
Serum uric acid in the upper quartile was associated with the highest odds ratio (OR) of PAD (for uric acid > 6.1 mg/dl, OR = 4.31; 95% CI, 1.49–12.44). The remaining variables more strongly associated with PAD were: Heart rate >90 bpm (OR = 4.16; 95% CI, 1.62–10.65), pulse pressure in the upper quartile (≥ 54 mmHg) (OR = 3.82; 95% CI, 1.50–9.71), adherence to Mediterranean diet (OR = 2.73; 95% CI, 1.48–5.04), and former smoker status (OR = 2.04; 95% CI, 1.00–4.16).

Conclusions
Our results show the existence of a low prevalence of peripheral artery disease in a population aged 45–74 years. Serum uric acid, pulse pressure and heart rate >90 bpm were strongly associated with peripheral artery disease. The direct association between Mediterranean diet and peripheral artery disease that we have found should be evaluated through a follow-up study under clinical practice conditions.

Introduction
Peripheral arterial disease (PAD) is an important marker of cardiovascular risk [1], and it is an indicator of widespread atherosclerosis in other vascular territories such as the coronary, carotid, and cerebrovascular arteries [2]. The annual mortality rate derived from epidemiological studies of patients with lower extremity PAD is high [3], with a combined event rate for myocardial infarction, stroke, and vascular death of 4% to 5% per year [4].

The ankle–brachial index (ABI) is the ratio of the ankle to brachial systolic blood pressure, and a value of <0.90 indicates the presence of a flow-limiting arterial disease affecting the limb. The accuracy of the ABI for detecting ≥50% stenosis in the leg arteries is high (75% sensitivity and 86% specificity) [5]. The American Heart Association (AHA) Prevention Conference V highlighted the a low ABI is a consistent independent risk factor for cardiovascular events and mortality and recommended its use to detect subclinical PAD [2, 6] to offer early therapeutic interventions to lower the risk of cardiovascular events and mortality. The prevalence of PAD ranges between 1.8% and 25% according to the population studied and the cut-off value of the ABI. In advanced countries it has reported to be 3–10% among those aged 40–70 years, and 10–20% among those over 70 years of age [7]. Data from the Multi-Ethnic Study of Atherosclerosis (MESA) showed that the prevalence of PAD was the same in men and women at 3.7%, but borderline values of ABI were significantly higher in women (10.6% vs. 4.3%) [8]. Likewise, the prevalence is higher in certain population subgroups such as diabetic patients [9] and smokers [10].

The Mediterranean Diet (MeDiet) is characterized by daily consumption of fruits, vegetables, legumes, grains, moderate alcohol intake (1–2 glasses/d of wine), a moderate-to-low consumption of red meat, and a high monounsaturated–to–saturated fat ratio [11].

The PREvención con DIeta MEDiterránea (PREDIMED) study [12] showed for the first time under a randomized controlled trial design that a MeDiet supplemented with either extra-virgin olive oil or nuts is useful in the primary prevention of cardiovascular disease (CVD), PAD, atrial fibrillation, and type 2 diabetes mellitus in individuals at high risk. However, few studies carried out under clinical practice conditions have studied the role of MeDiet on PAD, with unselected patients (with and without CVD) and with usual MeDiet consumption.
To date, five population-based studies [13–16] have been conducted in Spain, showing discordant results in PAD prevalence and associated factors, and none of them reported the influence of MeDiet. Furthermore, these studies were carried out in areas where the compliance to MeDiet is higher than in Madrid [17].

Moreover, serum uric acid is an independent risk factor for cardiovascular events [18], but few studies have explored the possible relationship between serum uric acid levels and PAD [19]. This association is plausible given the previous evidence that serum uric acid may affect vascular endothelial function [20], although the association remains controversial [21].

Lastly, pulse pressure (PP; difference between systolic and diastolic pressures) has been included as a predictor of ABI < 0.9 in the Spain REASON risk score, and a recently study using the NHANES data [22] has confirmed this issue. Adding pulse pressure to the periodic evaluation of high-risk patients might be a promising PAD surveillance instrument for the community-based population.

The objectives of the present study are to describe the prevalence of PAD in a random population sample and to evaluate its relationship with MeDiet, and with other potential cardiovascular risk factors such as serum uric acid and pulse pressure in individuals older than 45 years.

**Material and methods**

**Design**

This study was conducted as part of a broader project, the Screening PRE-diabetes and type 2 DIAbetes (SPREDIA-2) study, which has been described in detail elsewhere [23]. SPREDIA-2 is a population-based prospective cohort study in which baseline screening was performed from July 2010 to March 2014.

**Subjects**

A total of 2,553 subjects were contacted. Potential participants were selected randomly from the electronic health records of all patients with health care coverage from two districts in the north metropolitan area of Madrid (Spain), namely, Fuencarral-El Pardo and Tetuán, which include three and seven primary health care centers, respectively. Of the 1,592 subjects (62.4%) who agreed to participate, 166 had been diagnosed with DM.

Those subjects not interested in participating were asked to report voluntary sociodemographic and clinical data, which revealed no significant differences in age, sex, or BMI. However, subjects in the participants group had a significantly greater family history of DM, hypertension and dyslipidemia compared with the non-participants group (S1 Table). The study procedure has been described in detail elsewhere [23]. Briefly, recruitment was divided into three phases. First, the potential participants were sent a letter signed by their general practitioner explaining the objectives of the study and inviting them to participate. Second, subjects were contacted by phone to resolve doubts, and, if they were interested in participating, were given an appointment for the assessment. To minimize the losses attributable to failure to locate the patient, up to four telephone calls were made at different times and on different days. Third, the patient attended the assessment in the outpatient clinic of Carlos III Hospital after an overnight fast. Upon arrival, a fasting blood analysis was obtained by measuring blood levels of glucose, creatinine, serum uric acid, HbA1c, serum insulin, and lipids and lipoproteins. Immediately after blood sampling, all subjects with no previous diagnosis of diabetes underwent an oral glucose tolerance test (OGTT) with 75 g of anhydrous glucose in a total fluid volume of 300 ml. A second blood sample was obtained 2 hours later.
Variables

The ABI values were measured by nurses trained at the Section of Internal Medicine of The Carlos III Hospital and according to current recommendations [24]. The ABI measurements were performed with a bidirectional portable echo-Doppler of 8 MHz (Minidoppler HADECO ES-100, Kawasaki, Japan) and a calibrated sphygmomanometer. The systolic blood pressure (SBP) was measured in the posterior tibial and pedal arteries of both lower limbs and the brachial artery of both upper limbs. The value of the ABI for each limb was calculated dividing the greater SBP obtained in each limb by the SBP of whichever was the higher in the upper limbs. The lowest value obtained was considered the ABI for that individual.

Sociodemographic variables, family history of prevalent diseases, cardiovascular risk factors (smoking habit, hypertension, diabetes, and hypercholesterolemia), clinical history of cardiovascular disease (CVD), comorbidities, and current treatments were recorded for all individuals. Participants were considered as hypertensive when the arterial pressure was ≥140/90 mmHg. Hypercholesterolemia was defined as having LDL-cholesterol ≥100 mg/dl (2.57 mmol/l) and/or receiving hypolipidemic medication. The smoking habit included all who had consumed tobacco over the previous month. A diabetes diagnosis was established when baseline glucose was ≥7 mmol/l (126 mg/dl) on two different occasions, or if the patient was receiving oral hypoglycemic drugs or insulin. CVD included documented history of coronary heart disease (acute myocardial infarction, angina, coronary revascularization procedure), ischemic or hemorrhagic stroke, and PAD. All participants had a physical examination with determination of height, weight, waist circumference (midway between the lowest rib and the iliac crest), and blood pressure. PP was calculated as the difference between systolic and diastolic pressures.

A previously validated 14-item MeDiet Assessment Tool was the method for assessing adherence to the MeDiet [25] where subjects were asked for their consumption of the most common Mediterranean foods (S2 Table). The total score ranges from 0 to 14. Each item was scored 0 (non-compliant) or 1 (compliant) [26]. Higher scores reflected better adherence. High adherence was defined as meeting at least 11 of the 14 items [27].

Cholesterol and triglycerides were determined by enzymatic assays. Low-density lipoprotein cholesterol (LDL-cholesterol) was calculated according to the Friedewald formula (LDL-cholesterol = total cholesterol—([high-density lipoprotein cholesterol (HDL-cholesterol) + triglycerides/5]) in subjects with triglycerides below 400 mg/dl. HDL-cholesterol was measured after precipitation of apo-B lipoproteins. Glucose was measured by the glucose oxidase method. HbA1c was measured by a high-performance liquid chromatography (HPLC) method. Uric acid was measured by the uricase method.

Statistical analysis

The quantitative variables are presented as means with standard deviation, and the qualitative variables are presented as percentages. To check for normality of distribution of quantitative variables the Kolmogorov-Smirnov test was applied. Comparison of categorical variables was performed using chi-squared tests, and for continuous variables, the ANOVA test was used. The chi-square test for linear trend was used for ordinal variables. To explore associations across the range of ABI levels, ABI was categorized into 4 levels, with <0.9 or known PAD as the lowest level, and tertiles of ABI (0.90–1.09, 1.10–1.19 and ≥1.20, respectively). Logistic regression analyses were performed to evaluate the independent association of PAD with those variables that, in the univariate analysis, showed significance levels of P<0.10, as well as those that were considered clinically important or potentially confounding, such as gender and age. In the fully adjusted analysis, the interaction between gender and age was not significant. The
magnitude association was expressed with the Odds Ratio. In all cases, the accepted level of significance was 0.05 or less, with a 95% Confidence Interval (95% CI).

Statistical processing of the data was performed with SPSS v.19 software (IBM Inc, Armonk, NY, USA).

Ethical considerations
The study protocol had been approved by the Research Ethics Committee of the Carlos III Hospital in Madrid. The study complied with the International Guidelines for Ethical Review of Epidemiological Studies (Geneva, 1991). All patients signed an informed consent form.

Results
A total of 1,592 subjects agreed to participate in the study, 684 (43%) of whom were male. We excluded 6 participants who did not complete the ABI. Table 1 describes the characteristics of the study sample. From a total of 1,586 patients (mean age 61.5 years), 20 (1.3%) of them were previously diagnosed to have PAD (eight patients showed an ankle-brachial index [ABI] < 0.9 and twelve an ABI ≥ 0.9). Out of the 1,566 patients without a previous diagnosis of PAD, 40 (2.5%) showed an ABI < 0.9. The patients previously diagnosed to have PAD with an ABI ≥ 0.9 (n = 12) did not show differences in cardiovascular risk factors (hypertension, diabetes mellitus, dyslipidemia) or cardiovascular events (coronary artery disease, stroke) compared to individuals with an ABI < 0.90, who were defined as having newly diagnosed PAD (n = 48).

The patients previously diagnosed of PAD had a high morbidity in comparison with non-PAD patients [25% coronary artery disease vs. 3.4% (p < 0.001), higher prevalence of diabetes mellitus (41.7% vs. 10.2%; p < 0.001), hypercholesterolemia (75% vs. 47.8%; p = 0.06)], were more frequently treated with antiaggregants (41.7% vs. 8.8%; p < 0.001) and their adherence to MeDiet was moderately higher (25% vs. 18.7%; p = 0.58).

PAD prevalence was 3.81% (95% CI, 2.97–4.87) for all participants. In men the PAD prevalence was significantly higher than in women [5.17% (95% CI, 3.74–7.11) vs. 2.78% (95% CI, 1.89–4.07); p = 0.014]. The prevalence of PAD increased with age in men, from 3.8% in subjects aged < 60 years to 9% in those aged ≥ 70 years. In women, however, the prevalence decreased from 3.7% in subjects aged < 60 years to 1.2% in those aged ≥ 70 years (Fig 1A). Furthermore, the prevalence of PAD was lower in never-smokers than in current or former smokers (Fig 1B). Also, for former smokers the PAD prevalence in men was 2.25-fold greater than in women (6.3% vs. 2.8%), but we did not find large differences in the PAD prevalence for the current smoker population between both genders. We found positive associations between PAD and PP and serum uric acid values grouped in quartiles (Fig 2).

Patients in lower ABI categories were more likely to be older and male and to have a higher number of traditional cardiovascular disease risk factors (Table 2). There were statistically significant differences between ABI categories in relation to: smoking status, level of studies, coronary artery disease, hypertension, diabetes, hypercholesterolemia, systolic blood pressure, PP, heart rate, waist circumference, metabolic syndrome, HbA1c, serum uric acid, creatinine, and use of diuretics, beta-blockers, antiaggregant, renin-angiotensin system blockers and statins.

In the univariate analysis, the OR of PAD for male gender was 1.91 (95% CI, 1.13–3.22; p = 0.014). However, after fully adjusting for all covariates used in our analyses, the OR changed to a non-significant 1.30 (95% CI, 0.69–2.57; p = 0.40) for the female gender.

Table 3 shows the results of the individual analysis of the risk factors associated with the presence of PAD according to the multivariate logistic regression model adjusted for age, gender, and those variables with a p-value of less than 0.10 in the univariate analysis. Serum uric acid in the upper quartile was associated with the highest OR of PAD (for uric acid > 6.1 mg/
Table 1. Baseline characteristics of patients included in the study.

|                             | Total N = 1,586 |
|-----------------------------|-----------------|
| **Age (years), mean (SD)**  | 61.5 (6)        |
| **Gender (female) (%)**     | 57.0            |
| **Smoking**                 |                 |
| Current smoker (%)          | 16.1            |
| Former smoker (%)           | 37.1            |
| Never smoker (%)            | 46.8            |
| **Level of studies**        |                 |
| Elementary school (%)       | 9.7             |
| Junior High school (%)      | 31.1            |
| Senior High school (%)      | 27.1            |
| Graduate school (%)         | 32.2            |
| **History of**              |                 |
| Hypertension (%)            | 36.5            |
| Coronary Artery Disease (%) | 3.5             |
| Stroke (%)                  | 2.3             |
| Diabetes Mellitus (%)       | 10.4            |
| Hypercholesterolemia (%)    | 48.0            |
| **Anthropometries variables** |                 |
| Systolic Blood Pressure (mmHg), mean (SD) | 124.9 (17) |
| Diastolic Blood Pressure (mmHg), mean (SD) | 77.6 (9.9) |
| Pulse pressure, mmHg, mean (SD) | 47.3 (11.6) |
| Heart rate, beats/min, mean (SD) | 69.2 (10.7) |
| Waist circumference, cm, mean (SD) | 95.1 (12.3) |
| **BMI**                     |                 |
| BMI <25 Kg/m² (%)           | 23.9            |
| BMI 25–29 Kg/m² (%)         | 43.9            |
| BMI ≥30 Kg/m² (%)           | 32.2            |
| Metabolic syndrome (%)      | 39.5            |
| **Laboratory measures**     |                 |
| FPG (mg/dl), mean (SD)      | 105.9 (20.2)    |
| HbA1c (%), mean (SD)        | 5.80 (0.58)     |
| 2h-OGTT (mg/dl), mean (SD)  | 122.2 (43.0)    |
| 2h-OGTT ≥200 mg/dl (%)      | 5.7             |
| LDL-Cholesterol (mg/dl), mean (SD) | 132.8 (33.6) |
| HDL-Cholesterol (mg/dl), mean (SD) | 54.0 (14.6) |
| Total Cholesterol (mg/dl), mean (SD) | 207.4 (37.9) |
| Triglycerides (mg/dl), mean (SD) | 104.2 (69.9) |
| Serum Uric Acid, mg/dl, mean (SD) | 5.27 (1.30) |
| Creatinine, mg/dl, mean (SD) | 0.76 (0.21)    |
| eGFR <60 mL/min/1.73 m² (%) | 1.3             |
| Mediterranean diet score, mean (SD) | 8.6 (2.1) |
| Baseline score for Adherence to Mediterranean Diet >11 (%) | 18.7 |
| **Use of**                  |                 |
| Diuretics (%)               | 13.5            |
| Antiaggregants (%)          | 9.1             |
| Anticoagulants (%)          | 1.9             |

(Continued)
dl, PR = 4.31; 95% CI, 1.49–12.44). The remaining variables more strongly associated with PAD were: Heart rate > 90 bpm (OR = 4.16; 95% CI, 1.62–10.65), PP in the upper quartile (≥ 54 mmHg) (OR = 3.82; 95% CI, 1.50–9.71), adherence to MeDiet (OR = 2.73; 95% CI, 1.48–5.04), and former smoker status (OR = 2.04; 95% CI, 1.00–4.16).

### Discussion

The results of our study show that the prevalence of PAD is low in comparison with other international population-based studies [28], but similar to that found in the Hermex Study carried out in Badajoz (Spain) [29]. A recent systematic review for Peripheral Arterial Disease Research Coalition including 34 community-based studies [30] evidenced that prevalence of PAD ranged between 7.3–11.8% for women aged 50–74 years and between 6.4–12.1% for men aged 50–74 years among high-income countries. Spain belongs to the high-income countries category, and for this reason, one might expect a higher prevalence of PAD. However, a “Spanish paradox” has been described as a phenomenon by which the cardiovascular morbidity (myocardial infarction stroke and PAD) and mortality levels are dissociated from their cardiovascular risk factors. The existence of protector factors such as MeDiet and its interaction with different genetic patterns [31] has been argued as a plausible explanation of this phenomenon.

Furthermore, other Spanish population-based studies have shown PAD prevalence ranging from 4.5% [13] to 10.5% [16]. The prevalence was higher in men than in women for all Spanish studies. Nevertheless, some community-based studies have shown a higher prevalence of PAD in women compared with men [32–35], even in each decade of life [33]. These findings raise concerns about whether there should be differences in the definition of normal ABI values between men and women, and therefore whether the diagnostic criteria of PAD should be based on a cut-off ABI value different to the currently accepted as standard.

It is commonly accepted that men have a higher prevalence of PAD than women until the seventh decade of life [16, 29, 36]. However, in our study, the PAD prevalence was lower in women in comparison with men for each age group. Also, we found an inverse relationship between PAD and advancing age among women. We have no strong explanation for this finding, in which chance could indeed be playing a role.

The direct association between adherence to MeDiet and PAD is an unexpected phenomenon, given the strong evidence of the reduction of risk of PAD with the daily consumption of MeDiet [37]. Some aspects may explain our results. Firstly, the PREDIMED Randomized Trial compared two groups of MeDiet supplemented with extra-virgin olive oil and nuts, respectively, with a group who received counseling on a low-fat diet (control group), and all groups received a comprehensive dietary educational program based on individual and group sessions with a dietitian every 3 months designed to increase adherence to the MeDiet or a low-fat diet. The use of the 14-point MeDiet questionnaire proved very useful because the results formed...
Fig 1. Prevalence of PAD stratified by age group and gender (A) and by smoking status and gender (B).

https://doi.org/10.1371/journal.pone.0186220.g001
the basis for personalized advice on changes the participant should make to acquire a traditional MeDiet or low-fat diet pattern. However, in the present study, no person received counseling and/or supplements of diet. Quite simply, we merely asked them for their consumption of MeDiet using the 14-point MeDiet questionnaire. These differences might help explain our findings. Secondly, as it is well known, a cross-sectional study like ours does not allow the establishment of a causal relationship between MeDiet and PAD. Thus, patients with baseline known PAD might have initiated MeDiet as part of their treatment, given that these individuals with known PAD had high vascular morbidity and a trend to show a better adherence to MeDiet compared with those without PAD. Thirdly, is plausible that those patients with known PAD and those with compatible symptoms of PAD (i.e. intermittent claudication) would tend to conserve healthier diets like the MeDiet whereas the population with a good perception of their health would lead to a progressive abandonment of the MeDiet, due to the economic crisis. This phenomenon has been detected in Italy, with a dramatic fall in the adherence to MeDiet, lowering the adherence from over 30% to 18% in the whole population with the global economic crisis [38]. This hypothesis might partially explain the results obtained here.

The positive association between smoking status and PAD is well established, and it is habitually found in the vast majority of studies [14, 16, 30, 34]. Our study is consistent with these findings, but shows slight differences in the PAD prevalence between current and former smokers in the case of men. These findings are concordant with a recent systematic review of 34 studies [30]. However, other studies in our country showed greater differences between both levels of smoking status [14].

Our findings of a strong, independent association between serum acid uric >6.1 mg/dl and PAD is congruent with previous studies in adults with high cardiovascular risk [39, 40] and among the general population [41]. Serum uric acid has been found to be associated with several inflammatory markers, including C-reactive protein and interleukin-6 [42]. Furthermore, hyperuricemia has been reported as a factor responsible for cardiovascular diseases through endothelial dysfunction caused by inactivation of nitric oxide, which is a potent vasodilator [43], and arresting the proliferation of endothelial cells [44].

However, it is well known that there is a high correlation between serum uric acid and glomerular filtration rate (GFR), strengthening the possibility that Chronic Kidney Disease (CKD) status may be a statistical confounder in the relationship between uric acid and cardiovascular disease, rather than the mediator [45]. In recent years, a better understanding of uric acid metabolism suggests that CKD may be an intermediate step between hyperuricemia and cardiovascular disease, and increased levels of uric acid are, at once, a dependent and independent risk factor of cardiovascular disease and kidney disease progression [46].

As large-artery stiffness increases in middle-aged and elderly subjects, SBP rises, and DBP falls, with a resulting increase in PP [47]. A series of prospective and cross-sectional studies have shown that PP is associated with cardiovascular events [47–49] and mortality [47, 50–51].
Table 2. Demographic and clinical characteristics by ankle-brachial index (ABI) category.

| PAD/ABI <0.90 n = 60 | ABI 0.90–1.09 n = 498 | ABI 1.01–1.19 n = 503 | ABI > 1.19 n = 525 | p-value* |
|-----------------------|------------------------|------------------------|---------------------|----------|
| Age (years), mean (SD) | 62.4 (6)               | 61.9 (6)               | 61.5 (6.9)          | 61.4 (6) | 0.023    |
| Gender (female) (%)    | 41.7                   | 73.7                   | 57.5                | 42.5     | <0.001   |
| Smoking                |                        |                        |                     |          |          |
| Current smoker (%)     | 26.7                   | 17.1                   | 14.6                | 15.4     | 0.018    |
| Former smoker (%)      | 46.7                   | 33.3                   | 37.9                | 38.7     |          |
| Never smoker (%)       | 26.7                   | 49.6                   | 45.7                | 45.9     |          |
| Level of studies       |                        |                        |                     |          |          |
| Elementary school (%)  | 8.6                    | 13.7                   | 10.6                | 5.1      | <0.001   |
| Junior High school (%) | 41.4                   | 31.3                   | 29.7                | 31.0     |          |
| Senior High school (%) | 27.6                   | 29.7                   | 28.7                | 23.0     |          |
| Graduate school (%)    | 22.4                   | 25.3                   | 31.1                | 40.8     |          |
| History of             |                        |                        |                     |          |          |
| Hypertension (%)       | 51.7                   | 39.2                   | 33.8                | 34.7     | 0.017**  |
| Coronary Artery Disease (%) | 15             | 4.6                   | 2.8                | 1.9      | <0.001** |
| Stroke (%)             | 1.7                    | 2.2                    | 2.6                | 2.3      | 0.962    |
| Diabetes Mellitus (%)  | 21.7                   | 12.0                   | 10.3                | 7.6      | 0.001**  |
| Hypercholesterolemia (%) | 58.3               | 50.5                   | 47.2                | 45.1     | 0.024**  |
| Anthropometries variables |                    |                        |                     |          |          |
| Systolic Blood Pressure (mmHg), mean (SD) | 132.6 (18) | 125.8 (17) | 124.4 (17) | 123.6 (17) | 0.001    |
| Diastolic Blood Pressure (mmHg), mean (SD) | 78.9 (9.9) | 78.1 (9.7) | 77.7 (10.5) | 76.8 (9.7) | 0.123    |
| Pulse pressure, mmHg, mean (SD) | 53.7 (12.7) | 47.6 (12.5) | 46.7 (10.8) | 46.8 (11) | <0.001   |
| Heart rate, beats/min, mean (SD) | 71.9 (14) | 69.7 (10.7) | 69.4 (10.6) | 68.2 (10.2) | 0.025    |
| Waist circumference, cm, mean (SD) | 100.1 (12.8) | 93.9 (12.7) | 94.6 (11.8) | 96.1 (12.1) | <0.001   |
| BMI                    |                        |                        |                     |          |          |
| BMI <25 Kg/m2 (%)      | 16.7                   | 24.5                   | 27.0                | 21.1     | 0.063    |
| BMI 25–29 Kg/m2 (%)    | 41.7                   | 41.2                   | 42.1                | 48.4     |          |
| BMI >30 Kg/m2 (%)      | 41.7                   | 34.3                   | 30.8                | 30.5     |          |
| Metabolic syndrome (%) | 60.0                   | 41.8                   | 38.8                | 35.8     | 0.001**  |
| Laboratory measures    |                        |                        |                     |          |          |
| FPG (mg/dl), mean (SD) | 112.8 (26)            | 105.7 (20.5)           | 105.8 (20.4)        | 105.5 (18.8) | 0.066    |
| HbA1c (%), mean (SD)   | 6.07 (0.69)            | 5.86 (0.64)            | 5.80 (0.56)         | 5.72 (0.51) | <0.001   |
| 2h-OGTT (mg/dl), mean (SD) | 132.2 (53.5) | 120.9 (42.1) | 120.5 (39.1) | 123.9 (45.9) | 0.214    |
| 2h-OGTT >200 mg/dl (%) | 10.6                   | 5.6                    | 4.5                 | 6.5      | 0.272    |
| LDL-Cholesterol (mg/dl), mean (SD) | 134.5 (38.3) | 133.0 (34.8) | 133.7 (33.0) | 131.5 (32.5) | 0.722    |
| HDL-Cholesterol (mg/dl), mean (SD) | 51.5 (12.3) | 54.9 (14.8) | 54.7 (14.8) | 52.9 (14.4) | 0.060    |
| Total Cholesterol (mg/dl), mean (SD) | 209 (41) | 208.8 (39.6) | 208.2 (36.9) | 205.1 (36.9) | 0.391    |
| Triglycerides (mg/dl), mean (SD) | 115.7 (67.4) | 106.9 (78.1) | 100.7 (58.8) | 103.8 (71.5) | 0.318    |
| Serum Uric Acid, mg/dl, mean (SD) | 5.76 (1.4) | 5.09 (1.3) | 5.21 (1.28) | 5.45 (1.31) | <0.001   |
| Creatinine, mg/dl, mean (SD) | 0.83 (0.39) | 0.72 (0.18) | 0.75 (0.19) | 0.79 (0.21) | <0.001   |
| eGFR <60 mL/min/1.73 m2 (%) | 5.0               | 1.0                    | 1.4                 | 1.1      | 0.080    |
| Mediterranean diet score, mean (SD) | 8.8 (2.5) | 8.6 (2.1) | 8.7 (2.1) | 8.6 (2.1) | 0.657    |
| Baseline score for Adherence to Mediterranean Diet >11 (%) | 31.7 | 17.5 | 19.1 | 18.0 | 0.062 |
| Use of                |                        |                        |                     |          |          |
| Diuretics (%)          | 25.0                   | 15.1                   | 12.1                | 12.0     | 0.015**  |
| Antiaggregants (%)     | 28.3                   | 10.1                   | 7.8                 | 7.2      | <0.001** |
| Anticoagulants (%)     | 1.7                    | 2.2                    | 1.8                 | 1.7      | 0.938    |

(Continued)
Interest has been increasing on the association between PP and PAD. In this line, previous studies have shown an association between PP and PAD [52–54]. Our results are in accordance with these findings, but our study was carried out in a general population rather than a population with a high risk of cardiovascular disease as other studies [55,56]. The Multi-Ethnic Study of Atherosclerosis based in subjects free of cardiovascular disease has shown a tendency, though not statistically significant, to a higher proportion of patients with PAD for each 10 mmHg increase in PP [57].

To our knowledge, this is the second study that has shown an association between high heart rate and PAD. In The MERITO Study [58], for each increase in the heart rate of one beat per minute, the OR for PAD was 1.02 (96% CI, 1.01–1.03). Resting heart rate has been associated with all-cause and cardiovascular mortality [59,60]. Some studies have found indirect associations between heart rate and PAD. So, resting heart rate 77 beats/min has been associated with frailty in older men (age-adjusted OR = 1.90; 95%CI, 1.30–2.48) [61] and frailty is strongly associated with subclinical PAD (ABI < 0.8) (OR = 3.56; 95%CI, 2.03–6.24) [62].

A practical application of our findings is that heart rate > 90 beats/min and a serum uric acid above 6.1 mg/dl could be two factors to consider in selecting patients to screen for PAD, regardless of gender, age and diabetes status. Nevertheless, this proceeding requires caution because the pathophysiological basis of the relationship between resting heart rate and PAD is still unknown.

Other known factors firmly established to increase the risk of PAD, such as diabetes mellitus, hypertension, or hypercholesterolemia were not associated in the multivariate analysis with the presence of a low ABI. This is a phenomenon already observed in other studies [58,63,64], and may be due to the known limitations of cross-sectional studies, the lack of a sufficient number of cases of the disease or the exclusion of persons with an ABI > 1.5, who are more likely to have diabetes mellitus.

Concerning to the limitations of the study, the cross-sectional design did not allow determination of the causal effect of variables studied with PAD. Also, women were more likely to participate than men, as usually occurs in population-based studies. This aspect would limit the inference of the results to the entire population. Also, our findings about the magnitude of the association between both serum uric acid and high heart rates with PAD could have been affected by a potential residual confounding by unknown or misspecified confounding variables.

The study presents some strengths consisting of having collected epidemiological information on the prevalence of PAD in a sample of a wide range of ages, representative of the general population and from a region of our country with high prevalence of risk factors. Having used

---

Table 2. (Continued)

| PAD/ABI | Beta-blockers (%) | Calcium channel antagonists (%) | Renin-angiotensin system blockers (%) | Statins (%) |
|---------|------------------|---------------------------------|-------------------------------------|-------------|
| ABI < 0.90 n = 60 | 16.7 | 10.0 | 40.0 | 45.0 |
| ABI 0.90–1.09 n = 498 | 8.2 | 5.6 | 26.0 | 31.3 |
| ABI 1.10–1.19 n = 503 | 8.3 | 4.4 | 23.5 | 27.8 |
| ABI > 1.19 n = 525 | 6.1 | 6.1 | 24.4 | 23.0 |
| p-value* | 0.023** | 0.273 | 0.044 | <0.001** |

*p value for comparison between 4 categories of ABI (ANOVA test or Chi-squared test for means or proportions respectively).

**p value for linear trend (Chi-squared test for linear trend).

BMI: Body Mass Index; FPG: Fasting Plasma Glucose; eGFR: estimated Glomerular Filtration Rate; OGTT: Oral Glucose Tolerance Test.

https://doi.org/10.1371/journal.pone.0186220.t002
the same methodology as in other published population-based studies allows comparability to these.

In conclusion, our results demonstrate the existence of a low prevalence of PAD in a population aged 45–74 years. Serum uric acid, pulse pressure and heart rate >90 bpm were strongly

| Table 3. Factors associated with peripheral artery disease (logistic regression analysis). |
|---------------------------------|----------------|-----------------|----------------|
|                                | PR             | 95% CI          | p-value        |
| **Gender**                     |                |                 |                |
| Male                           | 1.00           |                 |                |
| Female                         | 1.301          | 0.661–2.562     | 0.446          |
| **Age** (per unit of increment)| 0.989          | 0.939–1.043     | 0.687          |
| **HbA1c** (per unit of increment)| 1.371          | 0.863–2.178     | 0.181          |
| **Antiaggregants**             |                |                 |                |
| No                             | 1.00           |                 |                |
| Yes                            | 2.373          | 0.983–5.727     | 0.055          |
| **eGFR <60 mL/min/1.73 m²**    |                |                 |                |
| No                             | 1.00           |                 |                |
| Yes                            | 2.178          | 0.526–9.027     | 0.283          |
| **Adherence of Mediterranean diet** |            |                 |                |
| No                             | 1.00           |                 |                |
| Yes                            | 2.729          | 1.479–5.036     | 0.001          |
| **Diuretics**                  |                |                 |                |
| No                             | 1.00           |                 |                |
| Yes                            | 1.985          | 0.907–4.342     | 0.086          |
| **Coronary Artery Disease**    |                |                 |                |
| No                             | 1.00           |                 |                |
| Yes                            | 1.971          | 0.592–6.567     | 0.269          |
| **Smoking**                    |                |                 |                |
| Never smoker                   | 1.00           |                 |                |
| Current smoker                 | 4.069          | 1.841–8.995     | 0.001          |
| Former smoker                  | 2.041          | 1.001–4.162     | 0.049          |
| **Serum Uric Acid**            |                |                 |                |
| 1st Quartile                   | 1.00           |                 |                |
| 2nd Quartile                   | 2.503          | 0.912–6.870     | 0.075          |
| 3rd Quartile                   | 1.667          | 0.546–5.088     | 0.369          |
| 4th Quartile                   | 4.314          | 1.496–12.446    | 0.007          |
| **Pulse pressure**             |                |                 |                |
| 1st Quartile                   | 1.00           |                 |                |
| 2nd Quartile                   | 1.201          | 0.411–3.508     | 0.738          |
| 3rd Quartile                   | 2.088          | 0.839–5.196     | 0.113          |
| 4th Quartile                   | 3.819          | 1.502–9.709     | 0.005          |
| **Heart rate >90 beats/min**   |                |                 |                |
| No                             | 1.00           |                 |                |
| Yes                            | 4.161          | 1.625–10.650    | 0.003          |

Adjusted for Diabetes (known and unknown), Arterial Hypertension, Metabolic syndrome Beta blockers, Renin-angiotensin system inhibitors and Statins use.
OR: Odds Ratio; CI: Confidence Interval; eGFR: estimated Glomerular Filtration Ratio.

https://doi.org/10.1371/journal.pone.0186220.t003

In conclusion, our results demonstrate the existence of a low prevalence of PAD in a population aged 45–74 years. Serum uric acid, pulse pressure and heart rate >90 bpm were strongly
associated with PAD. The direct association between MeDiet and PAD that we have found should be further evaluated through a follow-up study under clinical practice conditions.

Supporting information

S1 Table. Differences between participants and non-participants at recruitment phase. (DOCX)

S2 Table. Validated 14-item Questionnaire of Mediterranean diet adherence. (DOCX)

Acknowledgments

We would like to thank all members of the SPREDIA-2 Group: María Durán-Agüí, (Hospital La Paz), Alicia Cerón-Serrano (Hospital Carlos III), Leopoldo Pérez-Isla (Hospital Clínico de San Carlos), Ignacio Vicente (CS Monóvar), Sara Artola (CS Mª Jesús Herea), Mª Isabel Granados-Menéndez (CS Monóvar), Domingo Beamud-Victoria (CS Felipe II), Isidoro Dujovne-Kohan (CS Los Castillos), Rosa María Chico-Moraleja (Hospital Central de la Defensa), Carmen Martín-Madrazo (CS Monóvar), Juan Cárdenas-Valladolid (Gerencia de Atención Primaria), Rosario Echegoyen de Nicolás (CS Benita de Ávila), Concepción Aguilera Linde (CS Ciudad Periodistas), Álvaro Aguirre De Carcer Escolano (CS La Ventilla), Patricio Alonso Sacristán (CS Ciudad Periodistas), M Jesús Álvarez Otero (CS Dr Castroviejo), Paloma Arribas Pérez (CS Santa Hortensia), María Luisa Asensio Ruiz (CS Fuentelarreina), Pablo Astorga Díaz (CS Barrio Pilar), Beegoña Berriatua Ena (CS Dr Castroviejo), Ana Isabel Bezos Varela (CS José Marva), María José Calatrava Triguero (CS Ciudad Jardín), Carlos Casanova García (CS Barrio Pilar), Ángeles Conde Llorente (CS Barrio Pilar), Concepción Díaz Laso (CS Fuentelarreina), Emilia Elviro García (CS Ciudad Periodistas), Orlando Enriquez Dueñas (CS Fuentelarreina), María Isabel Ferrer Zapata (CS El Greco), Froilán Antuña (CS Ciudad Periodistas), María Isabel García Lazaro (CS Ciudad Periodistas), María Teresa Gómez Rodríguez (CS Barrio Pilar), África Gómez Lucena (CS La Ventilla), Francisco Herrero Hernández (CS La Ventilla), Rosa Julián Viñals (CS Dr Castroviejo), Gerardo López Ruiz Ogarrio “in memoriam” (CS Barrio Pilar), María Del Carmen Lumbrales Manzano (CS José Marva), Sonsoles Paloma Luquero López (CS Ciudad Periodistas), Ana Martínez Cabrera Peláez (CS Barrio Pilar), Montserrat Nieto Candenias (CS La Ventilla), María Alejandra Rabanal Carrera (CS Barrio Pilar), Ángel Castellanos Rodríguez (CS Ciudad Periodistas), Ana López Castellanos (CS La Ventilla), Milagros Velázquez García (CS Barrio Pilar) and Margarita Ruiz Pacheco (CS Dr. Castroviejo).

Lead author on behalf of the SPREDIA-2 group

Juan Cárdenas Valladolid, Dirección Técnica de Sistemas de Información Sanitaria, Gerencia Adjunta de Planificación y Calidad, Gerencia de Atención Primaria, Madrid, Spain. Email: juan.cardenas@salud.madrid.org

The MADIABETES Research Group (https://www.madiabetes.com) is a multidisciplinary group composed by general practitioner and nurses from 55 Health Centers of Madrid (Spain) who attended patients with Type 2 Diabetes Mellitus, and researchers of Public Centers, with a high interest to know the factors associated with the optimal evolution of the patients with this chronic disease.

Funding: This work was funded by the Agencia Lain Entralgo (Consejería de Sanidad de la Comunidad de Madrid) Grant ‘RS_AP10/6’ and by FIS (Fondo de Investigaciones Sanitarias, Instituto de la Salud Carlos III) grants no. PI12/01806 and PI15/00259 and co-financed by the
European Union through the Fondo Europeo de Desarrollo Regional (FEDER, “Una manera de hacer Europa”). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

Conceptualization: V. Cornejo del Río, J. Mostaza, C. Lahoz, C. de Burgos-Lunar, J. C. Abanades-Herranz, M. A. Salinero-Fort.

Data curation: C. de Burgos-Lunar, P. Gómez-Campelo, M. A. Salinero-Fort.

Formal analysis: J. Mostaza, C. Lahoz, P. Gómez-Campelo, M. A. Salinero-Fort.

Funding acquisition: J. C. Abanades-Herranz, M. A. Salinero-Fort.

Investigation: V. Cornejo del Río, J. Mostaza, C. Lahoz, V. Sánchez-Arroyo, C. Sabin, S. López, P. Patrón, P. Fernández-García, B. Fernández-Puntero, D. Vicent, L. Montesano-Sánchez, F. García-Iglesias, T. González-Alegre, E. Estirado, F. Laguna, C. de Burgos-Lunar.

Methodology: J. Mostaza, C. de Burgos-Lunar, M. A. Salinero-Fort.

Project administration: V. Cornejo del Río, C. de Burgos-Lunar, M. A. Salinero-Fort.

Resources: B. Fernández-Puntero, D. Vicent, L. Montesano-Sánchez, M. A. Salinero-Fort.

Software: B. Fernández-Puntero, L. Montesano-Sánchez, C. de Burgos-Lunar, P. Gómez-Campelo.

Supervision: V. Cornejo del Río, C. Lahoz, C. de Burgos-Lunar, M. A. Salinero-Fort.

Validation: B. Fernández-Puntero, L. Montesano-Sánchez, C. de Burgos-Lunar, J. M. de Miguel-Yanes, M. A. Salinero-Fort.

Visualization: J. M. de Miguel-Yanes, M. A. Salinero-Fort.

Writing – original draft: M. A. Salinero-Fort.

Writing – review & editing: V. Cornejo del Río, J. Mostaza, C. Lahoz, J. M. de Miguel-Yanes, M. A. Salinero-Fort.

References

1. Newman AB, Siscovick DS, Manolio TA, Pelak J, Fried LP, Borhani NO, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. 1993; 88(3):837–45. PMID: 8353913

2. Doobay AV, Anand SS. Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol. 2005; 25(7):1463–9. https://doi.org/10.1161/01.ATV.0000168911.78624.b7 PMID: 15879302

3. Cambou JP, Aboyans V, Constans J, Lacroix P, Dentans C, Bura A. Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France: the COPART Registry. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2010; 39(5):577–85.

4. Hirsch AT, Haskal ZJ, Hertzler NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006; 113(11):e463–654. https://doi.org/10.1161/CIRCULATIONAHA.106.174526 PMID: 16549646
10. Planas A, Clara A, Marrugat J, Pou J-M, Gasol A, de Moner A, et al. Age at onset of smoking is an independent risk factor in peripheral artery disease development. J Vasc Surg. 2002; 35(3):506–9. PMID: 11877699

11. Chrysohoou C, Esposito K, Giugliano D, Panagiotakos DB. Peripheral Arterial Disease and Cardiovascular Risk: The Role of Mediterranean Diet. Angiology. 2015; 66(8):708–10. https://doi.org/10.1177/0003197145565651 PMID: 25354501

12. Estruch R, Ros E, Salas-Salvadó J, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013; 368(14):1279–90. https://doi.org/10.1056/NEJMoa1203003 PMID: 23432189

13. Ramos R, Quesada M, Solanas P, Subirana I, Sala J, Vila J, et al. Prevalence of symptomatic and asymptomatic peripheral artery disease and the value of the ankle-brachial index to stratify cardiovascular risk. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2009; 38(3):305–11.

14. Aizamora MT, Forés R, Baena-Díez JM, Pera G, Toran P, Sorribes M, et al. The peripheral arterial disease study (PERA RT/ARTPER): prevalence and risk factors in the general population. BMC Public Health. 2010; 10:38. https://doi.org/10.1186/1471-2458-10-38 PMID: 20529387

15. Blanes JI, Cairols MA, Marrugat J, ESTIME. Prevalence of peripheral artery disease and its associated risk factors in Spain: The ESTIME Study. Int Angiol. 2009; 28(1):20–5. PMID: 19190551

16. Carbayo JA, División JA, Escrivano J, López-Abril J, López de Coca E, Artigaon LM, et al. Using ankle-brachial index to detect peripheral arterial disease: prevalence and associated risk factors in a random population sample. Nutr Metab Cardiovasc Dis. 2007; 17(1):41–9. https://doi.org/10.1016/j.numecd.2005.08.009 PMID: 17174225

17. Abellán Alemany J, Zafra Rentero MP, Monorro-García S, Mulero J, Pérez Garrido A, Leal M, et al. Adherence to the “Mediterranean Diet” in Spain and Its Relationship with Cardiovascular Risk (DIMER-ICA Study). Nutrients. 2016; 8(11). pii: E680.

18. Alderman MH. Serum uric acid as a cardiovascular risk factor for heart disease. Curr Hypertens Rep. 2001; 3(3):184–9. PMID: 11353567

19. Tseng C-H. Independent association of uric acid levels with peripheral arterial disease in Taiwanese patients with Type 2 diabetes. Diabet Med. 2004; 21(7):724–9. https://doi.org/10.1111/j.1464-5491.2004.01239.x PMID: 15209765

20. Ho W-J, Tsai W-P, Yu K-H, Tsay P-K, Wang C-L, Hsu T-S, et al. Association between endothelial dysfunction and hyperuricaemia. Rheumatology (Oxford). 2010; 49(10):1929–34.

21. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999; 131(1):7–13. PMID: 10391820

22. Zhang Y, Huang J, Wang P. A Prediction Model for the Peripheral Arterial Disease Using NHANES Data. Medicine (Baltimore). 2016; 95(16):e3454.

23. Salinero-Fort MÁ, de Burgos-Lunar C, Mostaza Prieto J, Lahoz Rallo C, Abánades-Herranz JC, Gómez-Campelo P, et al. Validating prediction scales of type 2 diabetes mellitus in Spain: the SPRE-DIA-2 population-based prospective cohort study protocol. BMJ Open. 2015; 5(7):e007195. https://doi.org/10.1136/bmjopen-2014-007195 PMID: 26220868

24. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012; 126(24):2890–909. https://doi.org/10.1161/CIR.0b013e318276fbb PMID: 23159553

25. Martínez-González MA, García-Arellano A, Toledo E, Salas-Salvadó J, Buil-Cosiales P, Corella D, et al. A 14-item Mediterranean diet assessment tool and obesity indexes among high-risk subjects: the
Prevalence of peripheral artery disease (PAD) and factors associated

26. Schröder H, Fité M, Estruch R, Martínez-González MA, Corella D, Salas-Salvadó J, et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. J Nutr. 2011; 141(6):1140–5. https://doi.org/10.3945/jn.110.135566 PMID: 21508208

27. Downer MK, Gea A, Stampfer M, Sánchez-Tainta A, Corella D, Salas-Salvadó J, et al. Predictors of short- and long-term adherence with a Mediterranean-type diet intervention: the PREDIMED randomized trial. Int J Behav Nutr Phys Act. 2016; 13:67. https://doi.org/10.1186/s12966-016-0394-6 PMID: 27297426

28. Hale WE, Marks RG, May FE, Moore MT, Stewart RB. Epidemiology of intermittent claudication: evaluation of risk factors. Age Ageing. 1988; 17(1):57–60. PMID: 3364312

29. Félix-Redondo FJ, Fernández-Bergés D, Grau M, Baena-Diez JM, Mostaza JM, Vila J. Prevalence and clinical characteristics of peripheral arterial disease in the study population Hermex. Rev Esp Cardiol (Engl Ed). 2012; 65(8):726–33.

30. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382(9901):1329–40. https://doi.org/10.1016/S0140-6736(13)61249-0 PMID: 23915883

31. Soriguer F, García-Escobar E, Morcillo S, García-Fuentes E, Rodríguez de Fonseca F, Oliveira G, et al. Mediterranean diet and the Spanish paradox: A hypothesis. Med Hypotheses. 2013; 80(2):150–5. https://doi.org/10.1016/j.mehy.2012.11.015 PMID: 23228554

32. Kullo IJ, Bailey KR, Kardia SLR, Mosley TH, Boerwinkle E, Turner ST. Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study. Vasc Med. 2003 Nov; 8(4):237–42. https://doi.org/10.1191/1358863x03vm511oa PMID: 15125483

33. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg. 2007; 45(6):1185–91. https://doi.org/10.1016/j.vasc.2007.02.004 PMID: 17543683

34. Zheng Z-J, Rosamond WD, Chambliss LE, Nieto FJ, Barnes RW, Hutchinson RG, et al. Lower extremity arterial disease assessed by ankle-brachial index in a middle-aged population of African Americans and whites: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Prev Med. 2005; 29(Suppl 1):42–9.

35. Hiramoto JS, Katz R, Ix JH, Wassel C, Rodondi N, Windham BG, et al. Sex differences in the prevalence and clinical outcomes of subclinical peripheral artery disease in the Health, Aging, and Body Composition (Health ABC) study. Vascular. 2014; 22(2):142–8. https://doi.org/10.1177/1708538113476023 PMID: 23512905

36. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation. 1997; 96(7):2468–82. PMID: 9337227

37. Ruiz-Canela M, Estruch R, Corella D, Salas-Salvadó J, Martínez-González MA. Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial. JAMA. 2014; 311(4):415–7. https://doi.org/10.1001/jama.2013.280618 PMID: 24449321

38. Bonaccio M, Di Castelnuovo A, Bonanni A, Persichillo M, et al. Decline of the Mediterranean diet at a time of economic crisis. Results from the Moli-sani study. Nutr Metab Cardiovasc Dis. 2014; 24(8):853–60. https://doi.org/10.1016/j.numecd.2014.02.014 PMID: 24819818

39. Zhan Y, Dong Y, Tang Z, Zhang F, Hu D, Yu J. Serum Uric Acid, Gender, and Low Ankle Brachial Index in Adults With High Cardiovascular Risk. Angiology. 2015; 66(7):687–91. https://doi.org/10.1177/0003319714566228 PMID: 25564679

40. Chen J, Mohler ER, Xie D, Shlipak MG, Townsend RR, Appel LJ, et al. Risk factors for peripheral arterial disease among patients with chronic kidney disease. Am J Cardiol. 2012; 110(1):136–41. https://doi.org/10.1016/j.amjcard.2012.02.061 PMID: 22465315

41. Shankar A, Klein BEK, Nieto FJ, Klein R. Association between serum uric acid level and peripheral arterial disease. Atherosclerosis. 2008; 196(2):749–55. https://doi.org/10.1016/j.atherosclerosis.2006.12.029 PMID: 17275005

42. Ruggiero C, Cherubini A, Ble A, Bos AJG, Maggio M, Dixit VD, et al. Uric acid and inflammatory markers. Eur Heart J. 2006; 27(10):1174–81. https://doi.org/10.1093/eurheartj/ehl879 PMID: 16611671

43. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A. 1989; 86(9):3375–8. PMID: 2497467
44. Sánchez-Lozada LG, Nakagawa T, Kang D-H, Feig DI, Franco M, Johnson RJ, et al. Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens. 2006; 15(1):30–3. PMID: 16340663
45. Tangri N, Weiner DE. Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles. Am J Kidney Dis. 2010; 56(2):247–50. https://doi.org/10.1053/j.ajkd.2010.06.004 PMID: 20659624
46. Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease?: Curr Opin Nephrol Hypertens. 2009; 18(6):526–30. https://doi.org/10.1097/MNH.0b013e328330d9d0 PMID: 19654543
47. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation. 1999; 100(4):354–60. PMID: 10421594
48. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertens. 1994; 23(3):395–401.
49. Selvaraj S, Steg PG, Elbaz Y, Sorbets E, Feldman LJ, Eagle KA, et al. Pulse Pressure and Risk for Cardiovascular Events in Patients With Atherothrombosis: From the REACH Registry. J Am Coll Cardiol. 2016; 67(4):392–403. https://doi.org/10.1016/j.jacc.2015.10.084 PMID: 26821627
50. Benetos A, Rudnichi A, Safar M, Guizé L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertens. 1998; 32(3):560–4.
51. Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL, Ducimetière P, et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertens. 1997; 30(6):1410–5.
52. Zhan Y, Yu J, Chen R, Sun Y, Fu Y, Zhang L, et al. Prevalence of low ankle brachial index and its association with pulse pressure in an elderly Chinese population: a cross-sectional study. J Epidemiol. 2012; 22(5):454–61. https://doi.org/10.2188/jei.JE20110140 PMID: 22813646
53. Ramos R, Baena-Díez JM, Quesada M, Solanas P, Subirana I, Sala J, et al. Derivation and validation of REASON: a risk score identifying candidates to screen for peripheral arterial disease using ankle brachial index. Atherosclerosis. 2011; 214(2):474–9. https://doi.org/10.1016/j.atherosclerosis.2010.11.015 PMID: 21167488
54. Zhan Y, Zhuang J, Dong Y, Xu H, Hu D, Yu J. Predicting the prevalence of peripheral arterial diseases: modelling and validation in different cohorts. VASA. 2016; 45(1):31–6. https://doi.org/10.1024/0301-1526/a000492 PMID: 26986707
55. Fan L-C, Chen M-Y, Huang W-C, Ho C, Chen P-Y, Huang J-C, et al. Pulse pressure and Michigan Neuropathy Screening Instrument are independently associated with asymptomatic peripheral arterial disease among type 2 diabetes community residents: a community-based screening program in Taiwan. Biomed J. 2013; 36(6):282–8. https://doi.org/10.4103/2319-4170.113371 PMID: 24385070
56. Korhonen P, Kautainen H, Aarnio P. Pulse pressure and subclinical peripheral artery disease. J Hum Hypertens. 2014; 28(4):242–5. https://doi.org/10.1038/jhh.2013.39 PMID: 24132137
57. Aboyans V, McClelland RL, Allison MA, McDermott MM, Blumenthal RS, Macura K, et al. Lower extremity peripheral artery disease in the absence of traditional risk factors. The Multi-Ethnic Study of Atherosclerosis. 2011; 214(1):169–73. https://doi.org/10.1016/j.atherosclerosis.2010.10.011 PMID: 21067754
58. Manzano L, Mostaza JM, Suárez C, Cairós M, Redondo R, Valdivielso P, et al. [Value of the ankle-brachial index in cardiovascular risk stratification of patients without known atherothrombotic disease. MERITO study]. Med Clin (Barc). 2007; 128(7):241–6.
59. Kristal-Boneh E, Silber H, Harati G, Froom P. The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J. 2000; 21(2):116–24. https://doi.org/10.1053/euhj.1999.1741 PMID: 10637085
60. Greenland P, Davilus ML, Dyer AR, Liu K, Huang CF, Goldberger JJ, et al. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in Industry. Am J Epidemiol. 1999; 149(9):853–62. PMID: 10221322
61. Ramsay SE, Arianayagam DS, Whincup PH, Lennon LT, Cryer J, Papacosta AO, et al. Cardiovascular risk profile and frailty in a population-based study of older British men. Heart. 2015; 101(8):616–22. https://doi.org/10.1136/heartjnl-2014-306472 PMID: 25480883
62. Newman AB, Gottdiener JS, Mcburnie MA, Hirsch CH, Kop WJ, Tracy R, et al. Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol Sci Med Sci. 2001; 56(3):M158–166. PMID: 11253157
63. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW f. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002; 143(6):961–5. PMID: 12075249
64. Vogt MT, Cauley JA, Kuller LH, Hulley SB. Prevalence and correlates of lower extremity arterial disease in elderly women. Am J Epidemiol. 1993; 137(5):559–68. PMID: 8465807